MedTrace Logo

A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants

NCT06503458 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2024-07-16

No results posted yet for this study

Summary

The purpose of this study is to learn more about painful crisis in people with Sickle Cell Disease. For this reason, Pfizer is conducting a study to understand how people with Sickle Cell Disease feel on a daily basis, treat these painful episodes including if they treat themselves at home or go to a doctor's office/emergency room, as well as the types of medications that are taken during these episodes.

Conditions

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Sanguine Biosciences

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-19
Primary Completion
2023-12-23
Completion
2024-04-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06503458 on ClinicalTrials.gov